Navigation Links
Healthcare Technologies Reports 2007 Nine Months & Third Quarter Results
Date:11/23/2007

PETACH TIKVA, Israel, November 23 /PRNewswire-FirstCall/ -- Healthcare Technologies, Ltd. (NASDAQ: HCTL), today announced unaudited results for nine months and the third quarter ended September 30, 2007.

Revenues for the third quarter of 2007 were $4.0 million, as compared to $3.1 million for the corresponding quarter last year. The third quarter gross profit was $1.4 million, as compared to $1.0 million in the third quarter of 2006. The net profit for the quarter was $189 thousand or $0.02 per share, compared to $34 thousand, or $0 per share for the third quarter of last year.

Revenues for the first nine months of 2007 were $11.7 million, compared to $10.1 million for the first nine months of 2006. The gross profit for the first nine months was $3.8 million versus $3.6 million for the same period in 2006. The net loss for the period was $130 thousand, or $0.02 per share, versus a net profit of $557 thousand, or $0.07 per share for the same period last year.

Shareholders' equity on September 30, 2007 was $7.1 million, compared to $7.3 million on December 31, 2006. Current assets net of current liabilities at the end of the period were $1.2 million, compared to $2.6 million on December 31, 2006.

About Healthcare Technologies

Healthcare Technologies Ltd. through it subsidiaries and affiliate Gamidor Diagnostics (1984) Ltd. ,Danyel Biotech Ltd. and Savyon Diagnostics Ltd., specializes in development, manufacturing and marketing of clinical diagnostic test kits and provides services and tools to diagnostic and biotech research professionals in laboratory and point of care sites worldwide.

Healthcare Technologies, Ltd.

Condensed Consolidated Statement of Operations

(U.S. Dollars in Thousands, Except Profit (Loss) Per Share Information)

Three Months Ended Nine Months Ended Year Ended

09/30/07 09/30/06 09/30/07 09/30/06 31/12/06

Sales $4,035 $3,066 $11,789 $10,116 $13,656

Gross profit $1,397 $1,025 $3,827 $3,591 $4,775

Net profit (Loss) $189 $34 $(130) $557 $210

Profit (Loss) per

share $0.02 $0.00 $(0.02) $0.07 $0.03

Weighted

average number

of Shares and

share equivalents

Outstanding

(in Thousands) 7,793 7,703 7,793 7,703 7,715

Consolidated Balance Sheet ,

(U.S $ in thousands)

09/30/07 09/30/06 12/31/06

Cash and cash

equivalents $238 $467 $361

Total current

assets $7,662 $7,055 $7,672

Total current

liabilities $6,442 $4,680 $5,055

Shareholder's

equity $7,151 $7,621 $7,315

Safe Harbor: This press release contains certain forward looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward looking statement made by or on behalf of Healthcare Technologies Ltd. Readers are referred to the documents filed by the company with the Securities Exchange Commission, specifically the most recent report on Form 20F that identifies important risks which could cause actual results to differ from those contained in the forward looking statements.

FOR: Healthcare Technologies Ltd

CONTACT: Eran Rotem CFO

+972-3-9277232/3


'/>"/>
SOURCE Healthcare Technologies Ltd
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
3. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
4. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
5. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
6. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
7. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
8. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
9. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
10. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
11. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... Denmark , March 22, 2017  Ascendis ... utilizes its innovative TransCon technology to address significant ... financial results for the full year ended December ... significant year for our company as we broadened ... a leading, integrated rare disease company with an ...
(Date:3/22/2017)...   iSpecimen ®, the marketplace for ... Service (DPS), a full-service anatomic pathology reference lab ... States , has joined a program offered by ... (DHIN) to make human biospecimens and associated data available ... announced in 2015 as a collaboration between iSpecimen and ...
(Date:3/22/2017)... Mass. , March 22, 2017   Boston ... next-generation cancer therapeutics designed to target cancer stemness pathways, ... Patricia S. Andrews as Chief Executive Officer, effective ... succeed Chiang J. Li , M.D., FACP, who ... ten years ago. Under his leadership, Boston Biomedical has ...
(Date:3/22/2017)... ... March 21, 2017 , ... ... To acquire information on the desired increase and/or decrease in antibody-dependent cellular cytotoxicity ... rapid N-glycosylation profiling of therapeutic antibodies. , To meet this demand, the ...
Breaking Biology Technology:
(Date:3/6/2017)... MATEO, Calif. , March 6, 2017 /PRNewswire/ ... marketing and sales technology, today announced Predictive Sales ... solution for infusing actionable sales intelligence into Salesforce. ... to automatically enable their sales organizations with deep ... messages that allow for intelligent engagement. Predictive Sales ...
(Date:3/2/2017)... LONDON , March 2, 2017 Summary ... require to better understand Merck KGaA and its partnering ... report: https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals ... into the partnering activity of one of the world,s ... reports are prepared upon purchase to ensure inclusion of ...
(Date:3/2/2017)... , March 2, 2017 Australian stem ... (ASX: CYP), has signed an agreement with the ... the Monash Biomedicine Discovery Institute and Department of Pharmacology ... conduct a further preclinical study to support the use ... of asthma.  Asthma is a chronic, ...
Breaking Biology News(10 mins):